Fermenta Biotech Limited

Fermenta Biotech Limited

Fermenta Biotech Limited has published a notice for a special window for transfer and dematerialisation of physical securities in Business Standard and Sakal newspapers.

Fermenta Biotech Limited

Fermenta Biotech Limited has informed the Exchange about a scheduled investor meeting on August 21, 2026, where the company's officials will discuss press releases and investor presentations available on the company's website.

Fermenta Biotech Limited

Fermenta Biotech Limited has informed the Exchange about Revision in Credit Rating, with CARE Ratings Limited upgrading the ratings for the company's long-term and short-term bank facilities.

Fermenta Biotech Limited

Fermenta Biotech Limited has published unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fermenta Biotech Limited

Fermenta Biotech Limited has declared the voting results of its 74th Annual General Meeting, with all resolutions passed with requisite majority.

Fermenta Biotech Limited

Fermenta Biotech Limited has submitted the voting results of its 74th Annual General Meeting held on August 11, 2026. The company has declared a dividend of Rs. 3.75 per equity share and has appointed a new director in place of Ms. Rajeshwari Datla. The resolutions were passed with the requisite majority.

Fermenta Biotech Limited

Fermenta Biotech Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026. The meeting approved the appointment of Ms. Rajeshwari Datla as a Non-Executive Director, payment of dividend of Rs. 3.75 per equity share, and material related party transactions between the Company and Fermenta USA LLC.

Fermenta Biotech Limited

Fermenta Biotech Limited has informed the Exchange about presentation to be made for shareholders at 74th Annual General Meeting of the Company.

Fermenta Biotech Limited

Fermenta Biotech Limited has announced its Q1FY27 earnings presentation, with revenue near flat sequentially at INR 126.2 crore, driven by a 24% QoQ increase in human nutrition revenue to INR 76.5 crore. The company's largest business segment, human nutrition, accounted for 61% of consolidated revenue. EBITDA declined 37% YoY to INR 9.5 crore, while profit after tax was down 56% YoY to INR 11.6 crore. The company has achieved two post-quarter milestones, including FSSAI approval for VITADEE Green for health supplements, nutraceuticals, and food products, and a 7th-place ranking nationwide in India's Great Mid-size Workplaces 2026.

Fermenta Biotech Limited

Fermenta Biotech Limited has announced its unaudited financial results for Q1FY27, with consolidated revenue of INR 126.2 crore, down 13% YoY and flat QoQ. EBITDA (excluding real estate) was INR 22.3 crore, down 37% YoY and 10% QoQ. The company's human nutrition segment volumes grew 18% QoQ and were down 21% YoY.

Fermenta Biotech Limited

Fermenta Biotech Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and has received an unmodified opinion from its statutory auditors.

Fermenta Biotech Limited

Fermenta Biotech Limited has informed the Exchange about a scheduled meeting with investors on August 17, 2026, in Mumbai. The meeting will be held in person and will discuss the company's press releases and investor presentations available on the company's website. No unpublished price-sensitive information will be discussed during the meeting.

Fermenta Biotech Limited

Fermenta Biotech Limited has announced the listing of its equity shares on the National Stock Exchange of India Limited (NSE) under the symbol FERMENTA and ISIN INE225B01021, effective August 4, 2026.